


Patent Claims

1. A compound of formula I

5



10

in which

R is -OH, -OA, phenoxy, Ar, -O-CO-A, SO₃H, SO₃A, -OSO₃H, -OSO₃A, -OSO₂A, SO₂A, Hal, COOH, COOA, CONH₂, NHSO₂A, COA, CHO or SO₂NH₂, or

15

two radicals R together are methylenedioxy or ethylenedioxy,

X is OH, or

two radicals X together are methylenedioxy or ethylenedioxy,

Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by A,

20

A is an unbranched or branched alkyl having 1-10 carbon atoms, in which 1-7 H atoms are optionally replaced by F,

Hal is F, Cl, Br or I,

n is 1, 2, 3 or 4, and

25

m is 1, 2, 3, 4 or 5, or

a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

30

2. A compound according to Claim 1,

in which

R is -OH or -OA, and

X is OH, or


a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof.

35

3. A compound according to Claim 1,
in which
- 5 R is -OH or -OA,
 X is OH,
 A is an unbranched or branched alkyl having 1-6 carbon
 atoms,
 n is 1 or 2, and
10 m is 1, 2 or 3, or
 a salt or a solvate or a mixture of stereoisomers or isolated
 stereoisomer thereof.
- 15 4. A compound according to Claim 1,
 in which
 R is -OH or -OA, or
 two radicals R together are methylenedioxy or ethylenedioxy,
 X is OH,
20 A is an unbranched or branched alkyl having 1-6 carbon
 atoms,
 n is 1 or 2, and
 m is 1, 2 or 3, or
25 a salt or a solvate or a mixture of stereoisomers or isolated
 stereoisomer thereof.
- 30 5. A compound according to Claim 1 selected from
 5-hydroxy-2-(2',4'-dihydroxybenzoyl)chromone,
 5-hydroxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone,
 6-hydroxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone, or
 6,7-methylenedioxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)-
 chromone, or
35 a salt or a solvate or a mixture of stereoisomers or isolated
 stereoisomer thereof.


6. A process for preparing a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof comprising

a) reacting a compound of formula II




in which

15 X and n are as defined in Claim 1,
with a compound of formula III




25 in which A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
to give a compound of formula IV




35 in which X and n are as defined in Claim 1, and A is alkyl having 1, 2,
3, 4, 5 or 6 carbon atoms,

- b) then hydrolysing the compound of formula IV to a compound of formula V




10 in which X and n are as defined in Claim 1,

- c) then converting the compound of formula V to a compound of formula VI



20 in which X and n are as defined in Claim 1,
and then reacting the compound of formula VI with a compound of formula VII



in which R and m are as defined in Claim 1,
in a Friedel-Crafts acylation to give a compound of the formula I,

30 and/or

- d) a compound of formula I is converted into a salt or into a solvate
and/or a stereoisomer of a compound of formula I is isolated.

35


- 5
7. A pharmaceutical composition comprising a compound according to Claim 1 or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof and one or more pharmaceutically acceptable excipients and/or adjuvants.
- 10
8. A method of inhibiting tyrosine kinase comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 15
9. A method of treating a solid tumor in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 20
10. A method according to Claim 9, wherein the solid tumor is a cerebral tumor, a tumor of the genito-urinary tract, a tumor of the lymphatic system, a stomach tumor, a laryngeal tumor or a lung tumor.
- 25
11. A method according to Claim 9, wherein the solid tumor is monocytic leukaemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma.
- 30
12. A method of treating a disease by inhibiting angiogenesis in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 35
13. A method according to Claim 12, wherein the disease is an ocular disease.
14. A method of treating retinal vascularisation in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

15. A method of treating diabetic retinopathy in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 5 16. A method of treating an age-related macular degeneration in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 10 17. A method of treating an inflammatory disease in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 15 18. A method according to claim 17, wherein the inflammatory disease is rheumatoid arthritis, psoriasis, contact dermatitis or a delayed hypersensitivity reaction.
- 20 19. A method of treating a tyrosine kinase-dependent disease or a tyrosine kinase-dependent condition in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 25 20. A method of treating a bone pathology comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.
- 30 21. A method according to claim 20, wherein the bone pathology is osteosarcoma, osteoarthritis or rickets.
22. A pharmaceutical composition according to claim 7, further comprising an additional pharmaceutically active compound.
- 35 23. A kit comprising separate packs of

- (a) a pharmaceutical composition according to Claim 7 or a compound of formula I or a salt or a solvate or a mixture of stereoisomers or isolated stereoisomer thereof,
and
5 (b) an additional pharmaceutically active compound or composition.
24. A method according to claim 9, further comprising administering an oestrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic agent, an antiproliferative
10 agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor or an angiogenesis inhibitor.
- 15 25. A method according to claim 24, further comprising performing radiotherapy on said mammal.
26. A method of treating a disease related to an oxidative stress condition in a mammal comprising administering to a patient in need
20 thereof a pharmaceutical composition according to claim 7.
27. A method according to claim 25, wherein the disease is memory loss or a neurodegenerative disorder.
25
28. A food supplement comprising a compound of claim 1.
29. A cosmetic composition comprising a compound of claim 1.
- 30 30. A method of protecting the proteins of the skin from stress comprising applying a cosmetic composition of claim 29 to the skin.
- 35 31. A topically applicable cosmetic composition comprising a compound of claim 1.

32. A cosmetic composition according to claim 29, containing 0.0001 to 50% by weight of a compound of claim 1.

33. A compound of formula VI



in which

X is OH , or

two radicals X together are methylenedioxy or ethylenedioxy, and

n is 1, 2, 3 or 4, or a

salt thereof.